GlassScriptPhysician profile
Stephanie Jo Herrera
NPI 1245534064
$2,903.47
in general payments reported to CMS, 2019-2025
16 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $228 · 2021: $811 · 2022: $351 · 2023: $362 · 2024: $354 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $848.49 | 2023-2025 | Inspire |
| Stryker Corporation | $502.65 | 2019-2022 | |
| Galderma Laboratories, L.P. | $350.41 | 2021 | |
| Optinose US, INC. | $260.41 | 2020-2025 | |
| Hill Dermaceuticals, INC. | $228.86 | 2022 | |
| Xoran Technologies LLC | $141.67 | 2021 | |
| Aerin Medical INC. | $123.16 | 2021 | |
| Intersect Ent, INC. | $115.31 | 2019 | |
| Medtronic, INC. | $83.12 | 2024-2025 | Propel, Nim-Response |
| Alk-Abello, INC | $76.97 | 2021-2022 | |
| Medtronic USA, INC. | $65.36 | 2019 | |
| Acclarent, INC | $43.61 | 2022-2023 | Acclarent Aera |
| Merz Pharmaceuticals, LLC | $22.29 | 2023 | Xeomin |
| Smith+Nephew, INC. | $14.69 | 2021 | |
| Merck Sharp & Dohme LLC | $14.37 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.